Compare GE & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GE | GILD |
|---|---|---|
| Founded | 1892 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.8B | 187.5B |
| IPO Year | 2008 | 2000 |
| Metric | GE | GILD |
|---|---|---|
| Price | $327.33 | $148.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 18 |
| Target Price | ★ $337.50 | $146.50 |
| AVG Volume (30 Days) | 4.1M | ★ 5.9M |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | 0.58% | ★ 2.21% |
| EPS Growth | 35.89 | ★ 1684.21 |
| EPS | ★ 8.14 | 6.78 |
| Revenue | ★ $45,855,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $8.18 | $4.68 |
| Revenue Next Year | $10.10 | $6.10 |
| P/E Ratio | $40.16 | ★ $21.94 |
| Revenue Growth | ★ 18.48 | 9.98 |
| 52 Week Low | $159.36 | $95.30 |
| 52 Week High | $348.48 | $157.29 |
| Indicator | GE | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 55.29 |
| Support Level | $288.37 | $143.09 |
| Resistance Level | $332.79 | $157.29 |
| Average True Range (ATR) | 9.95 | 3.15 |
| MACD | -2.43 | -1.12 |
| Stochastic Oscillator | 42.53 | 56.94 |
GE Aerospace is the global leader in designing, manufacturing, and servicing commercial aircraft turbine engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 80,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000 until GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).